Finally, we show how our PM tool can be used to generate novel hypotheses by comparing melanoma patients that progressed after a first line of ICI and who were treated with either a targeted treatment (BRAF inhibitors) or with an ICI rechallenge. The gene discussed is BRAF; the disease is melanoma.